Hims & Hers Health (NYSE:HIMS) Trading Up 2.5% - Here's What Happened

Key Points

• Hims & Hers Health's share price increased by 2.5% to $44.06, despite a significant drop in trading volume, down 78% from the average.
• The company's latest earnings report showed a miss in EPS estimates at $0.17, compared to an expectation of $0.18, with revenue also falling short of estimates.
• Multiple analysts have issued a "hold" rating on the stock, with Truist Financial lowering their target price from $48.00 to $37.00.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s share price was up 2.5% during trading on Tuesday . The company traded as high as $44.42 and last traded at $44.06. Approximately 7,467,648 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 33,461,629 shares. The stock had previously closed at $42.99.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on HIMS shares. Truist Financial lowered their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research note on Monday, August 18th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Morgan Stanley restated an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Finally, Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Trading Up 5.8%

The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The business has a 50-day moving average price of $51.37 and a two-hundred day moving average price of $45.85. The company has a market cap of $10.28 billion, a P/E ratio of 56.88, a P/E/G ratio of 3.01 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,107 shares of the company's stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the sale, the chief financial officer directly owned 63,222 shares of the company's stock, valued at $2,987,239.50. This represents a 26.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Michael Chi sold 17,102 shares of the business's stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total value of $1,021,844.50. Following the transaction, the insider directly owned 278,654 shares of the company's stock, valued at $16,649,576.50. The trade was a 5.78% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,392,857 shares of company stock valued at $71,746,999 over the last three months. 13.71% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Virtus Advisers LLC bought a new stake in shares of Hims & Hers Health in the 2nd quarter worth $26,000. Quaker Wealth Management LLC bought a new position in Hims & Hers Health during the second quarter valued at approximately $29,000. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health during the 1st quarter valued at about $30,000. Bessemer Group Inc. grew its holdings in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after purchasing an additional 312 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ boosted its position in Hims & Hers Health by 408.2% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock valued at $37,000 after buying an additional 600 shares during the period. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.